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Abstract
Background: Larger insulinomas are reportedly more likely to be malignant; however, their biological behavior has
not been clearly elucidated. We here report the characteristics and treatment of a giant insulinoma with local
invasion and lymph node metastasis. We also review published reports concerning the clinical features of giant
insulinomas and comparing their grading with that of pancreatic neuroendocrine tumors.
Case presentation: A 71-year-old man was referred to our hospital for investigation of persistent hypoglycemia.
On the current presentation, laboratory tests showed serum glucose, immunoreactive insulin, and C peptide
concentrations of 45 mg/dL, 17.2 μIU/mL and 4.1 ng/mL, respectively. Dynamic magnetic resonance imaging showed a
hypervascular tumor measuring 13.5 cm in the head of the pancreas. Computed tomography scanning demonstrated
local invasion and lymph node involvement. He thus had Whipple’s triad, which is associated with malignant insulinoma.
No distant metastases having been identified, pancreaticoduodenectomy was performed. Intraoperatively, three separate
tumors were identified in the pancreatic head. Pathological examination showed all three tumors were pancreatic
neuroendocrine tumors; the tumor cells in the largest mass were strongly immunoreactive for insulin. The Ki-67 index
was 2–5% in most parts of the largest tumor and over 20% in the poorly differentiated areas. This tumor was classified as
neuroendocrine carcinoma in accordance with the 2010 World Health Organization classification of pancreatic endocrine
neoplasms. He remains free of evidence of recurrence 2 years postsurgery.
A review of published reports indicated that giant insulinomas are more malignant than smaller ones, and metastatic
disease is found on presentation in 56% of patients with giant insulinomas; however, we were unable to identify any
correlation between grade of pancreatic neuroendocrine tumor and biological behavior of giant insulinomas.
Conclusions: Giant insulinomas more frequently exhibit malignant behavior, such as local invasion, lymph node
involvement, and liver metastasis, than smaller ones. However, there was no relationship between grade and rate of
metastases or survival in this small case series. Identification of useful biological markers is necessary.
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Background
Insulinomas are the commonest functioning pancreatic
neuroendocrine tumor (pNET); their estimated annual
incidence being one to three cases per million [1]. Approxi-
mately 10% are multiple and approximately 5% are associ-
ated with multiple endocrine neoplasia type 1 (MEN1)
syndrome [2]. Their mean size is 1.5 cm; 24% are smaller
than 1 cm, 42% 1–2 cm, 30% 2–3 cm, and approximately
4% >3 cm [3]. Malignancy is defined by the presence of
metastases, most commonly in lymph nodes or the liver;
the clinical presentation characteristically does not enable
differentiating benign from malignant disease [4]. Clinico-
pathological evidence of malignant behavior (gross local in-
vasion or metastases) is extremely rare in insulinomas,
occurring in only 5–10% of all insulinomas; thus, most can
be surgically cured [2].
Larger insulinomas are more likely to be malignant
[5]; however, their biological behavior has not been clearly
elucidated. Some authors have defined “giant” insulinomas
as ≥9 cm in largest dimension [6, 7]. We here report the
characteristics and treatment of a giant insulinoma with* Correspondence: kafureyuharyo@gmail.comDepartment of Surgery, Hitachi General Hospital, 2-1-1 Jonan-cho, Hitachi,
Ibaraki 317-0077, Japan
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peripancreatic local invasion and lymph node metastasis
and present a review of published reports.
Case presentation
A 71-year-old man was referred to our hospital for in-
vestigation of hypoglycemia. Two years before, he had
attended the emergency department with acute-onset
loss of consciousness after a traffic accident. Hypoglycemia
was identified as the cause; however, because his condition
had quickly improved, he was not extensively investigated
and was discharged without a definitive diagnosis. Since
then, he had recurrent hypoglycemia associated with
impaired consciousness. In the four preceding months,
his serum glucose concentrations had been less than
67 mg/dL and he had been given intravenous glucose,
which resulted in gradual resolution of symptoms.
On this presentation, his serum glucose, immunoreactive
insulin and C peptide concentrations were 45 mg/dL,
17.2 μIU/mL, and 4.1 ng/mL, respectively. MEN-1 syn-
drome was excluded by normal serum intact parathyroid
hormone, calcium, and prolactin concentrations. He thus
had Whipple’s triad (symptoms known or likely to be
caused by hypoglycemia, low serum glucose at the time of
the symptoms, relief of symptoms when the glucose has in-
creased to normal). To confirm the diagnosis of endogen-
ous hyperinsulinemia caused by insulinoma, the patient
underwent a supervised overnight fast during which he de-
veloped symptomatic hypoglycemia with serum glucose of
50 mg/dL.
Dynamic magnetic resonance imaging showed a
13.5 cm × 12 cm × 8 cm hypervascular tumor containing
necrotic areas in the pancreatic head (Fig. 1a). Magnetic
resonance cholangiopancreatography showed no involve-
ment of the pancreatobiliary systems (Fig. 1b). Com-
puted tomography scan demonstrated a heterogenous,
enhancing, partly necrotic mass partially replacing the
head of the pancreas (Fig. 2a). There was no evidence of
hepatic metastasis; however, local invasion of the surround-
ing adipose tissues and duodenum and lymph node involve-
ment were identified (Fig. 2b). This patient’s pancreatic body
and tail were slender, measuring 2 cm× 1.5 cm× 5 cm; no
other tumors were identified in them (Fig. 2c). No distant
metastases having been identified; extended pancreatic re-
section was performed.
Intraoperatively, one bulky tumor and two additional
undiagnosed tumors were identified in the head of the
pancreas. Manual palpation by an experienced surgeon
revealed no tumor in the pancreatic body and tail. One
3.5-cm diameter pedunculated lesion was suspended
from the surface of the uncinate process of the pancreas,
and another 2-cm diameter tumor was attached to the
duodenum. The patient underwent a subtotal stomach-
preserving pancreaticoduodenectomy.
Macroscopically, the largest tumor measured 15 × 9 ×
9 cm and was firmly adherent to the retroperitoneum
(Fig. 3a). Cut sections showed a solid lesion with evidence
of hemorrhage (Fig. 3b). All three tumors were composed
of uniform bland cuboidal cells with granular eosinophilic
cytoplasm and round nuclei. Most of the largest mass
comprised well-differentiated tumor cells (Fig. 4a); how-
ever, poorly differentiated tumor cells were identified in a
small part of it (Fig. 4b). The retroperitoneal fat tissues
and duodenum were involved, and metastases were
identified in two of four peripancreatic lymph nodes.
Immunohistochemically, the tumor showed strong dif-
fuse expression of chromogranin A, insulin, and gluca-
gon and weak expression of somatostatin. The Ki-67
index was 2–5% in most of the largest tumor (Fig. 4c)
but over 20% in the poorly differentiated areas (Fig. 4d).
This tumor was classified as a NEC in accordance with
the 2010 World Health Organization (WHO) classifica-
tion of pancreatic endocrine neoplasms.
Postoperatively, a moderate pancreatic fistula developed.
This resolved with conservative treatment and he was
discharged on postoperative day 35. At a routine
a
b
Fig. 1 Dynamic magnetic resonance image showing a 13.5 × 12 ×
8 cm hypervascular tumor containing necrotic areas in the pancreatic
head (a). Magnetic resonance cholangiopancreatography showing no
evidence of involvement of pancreatobiliary trees (b)
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follow-up visit 3 months postoperatively, he reported
no hypoglycemic symptoms, and he remains free of evi-
dence of recurrence 2 years and 3 months after surgery.
Discussion
Because it has been difficult to differentiate between be-
nign and malignant insulinomas on the basis of histologic
findings, malignant insulinomas have been diagnosed
based on metastasis to liver, lymph nodes, or other organs
[2]. However, the new 2010 “WHO Classification of Tu-
mors of the Digestive System” considers all insulinomas of
0.5 cm or greater malignant tumors [8]. According to the
2010 European Neuroendocrine Tumor Society guide-
lines, the most critical prognostic factors are the prolifera-
tive rate (mitotic index or Ki-67 labeling index) and the
presence of distant metastases [9].
Surgery is the only potentially curative treatment for
malignant insulinoma diagnosed at a locally advanced
stage [10]. The median disease-free survival after curative
resection is 5 years; recurrence occurs in more than 60% of
patients at a median interval of 2.5–3 years [2]. Patients
with distant metastases from insulinomas to the liver, bone,
and lymph nodes have a median survival of <2 years [11].
Callacondo et al. [12] reviewed 35 cases of giant insuli-
noma and reported that they are more likely to be malig-
nant than non-giant insulinomas; however, the relationship
between clinical features, pNETs grading, and G1/G2/




Fig. 2 Computed tomography scan image demonstrating a
heterogenous enhancing mass with areas of necrosis replacing the
head of the pancreas (a). Computed tomography scan image
demonstrating local invasion into the peripancreatic retroperitoneum
and duodenum (arrowhead) and lymph node involvement (arrow) (b).
No other hypervascular insulinomas were identified in the pancreatic
body and tail (arrow) (c)
a
b
Fig. 3 Macroscopic findings. Three separate tumors are present in
the head of the pancreas, namely, the largest, which was firmly
adherent to the retroperitoneum, a 2 × 2 cm tumor, which was
adherent to the duodenum (arrow), and a 3.5 × 2.5 cm pedunculated
tumor that was suspended from the surface of the uncinate process of
the pancreas (arrowhead) (a). The largest mass measured 15 × 9 × 9 cm
and the cut surface showed solid tissue with hemorrhagic areas (b)
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of giant insulinoma comprising the 35 cases of Callacondo
et al., an additional 9 cases [4, 5, 13–19] and the present
case (Table 1). We also investigated the relationship be-
tween recurrence rates and grade in reported cases
(Table 2). We performed a PubMed search and Japanese
MEDLINE databases (during the period of 1975–2015)
using the keywords: “giant insulinoma,” “malignant
insulinoma,” and “pancreatic neuroendocrine tumor” and
limited our review to reports in English- and Japanese-
language publications, including case reports.
The mean age at presentation of the 45 patients with





Fig. 4 Well-differentiated tumor cells were observed in most parts of
the tumor (a); however, poorly differentiated tumor cells were identified
in a small proportion of it (b). The Ki67 index was 2–5% in most of
the tumor (c); however, the poorly differentiated area had a Ki67 of
over 20% (d)
Table 1 Clinical features of 45 reported pancreatic giant
insulinomas
Variables
Age (mean) 15–83 (57) years
Sex (M:F) 1.14:1
Tumor diameter (mean) 9–21 (12) cm
Location
H/HB/B/BT/T/HBT/NA 3/1/2/13/22/1/3
Treatment for primary disease







Treatment of recurrences or remnant
Surgery/Syst chemo/HACE/RT/none/NA 3/2/2/2/1/7
Outcome (n) Duration of follow-up
(mean) months
No disease recurrence (24) 3–276 (18)
Alive with disease (6) 15–204 (48)
Died of metastatic disease (10) 1–156 (24)
Died of other disease (1) NA
NA (4) NA
H head, HB head and body, B body, BT body and tail, T tail, HBT head, body
and tail, NA not available, DP distal pancreatectomy, +/− with/without, S
splenectomy, RLM resection for liver metastases, ALM ablation of liver
metastases, PD pancreaticoduodenectomy, TP total pancreatectomy, E
enuclation, TR tumor resection, Biopsy biopsy of pancreatic or liver tumor, NO
no operation, Generalized involvement of the liver and one or more of the
following organs: adrenal glands, spleen, stomach, and colon, LN lymph node,
Surround surrounding tissue, Remnant remnant disease, Syst chemo systemic
chemotherapy, HACE hepatic arterial chemoembolization, RT radiation therapy
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Table 2 Clinicopathological features and grade of giant insulinomas in reports published since 2001
Author [ref]/year Age Sex Size (cm) Location Surgery Ki-67 (%) Mitosis Differentiation Grade Meta site at diagnosis Recurrences Follow-up (months)
Konno [14]/2001 40 F 10.5 Tail DP, S <2 NA NA 1 None None NDR (24)
Mittendorf [6]/2005 65 F 9 Tail Tumor resection >2 <1 W 2 None None NDR (6)
Esteban [12]/2008 57 F 10 Tail DP 20 NA W NEC None None NDR (31)
Rega [12]/2009 60 M 15 Body/tail DP, S 5.4 NA WDEC 2 Surround, LN None NDR (3)
Sugiyama [7]/2010 50 M 12 Head PD 1–2 1 W 1 Surround None NDR (12)
Matkari [12]/2010 32 M 11 Head E >2 NA W 2 None None NDR (12)
Pramodh [12]/2010 81 M 9.8 NA NO <5 NA WDEC 2 None None DOD (NA)
Oberheim [21]/2011 58 F 13.5 Head/body PpPD <1 1 W 1 None None NDR (12)
Callacondo [12]/2013 67 F 15 Tail DP, S, RLM <1 <1 W 1 Liver Liver AD (60)
Callacondo [12]/2013 63 M 10 Tail DP, S <2 5 W 1 LN Liver NDR (43)
Callacondo [12]/2013 38 M 11 Tail DP, S, RLM <2 3 W 2 Spleen, liver Liver DMD (156)
Ielpo [13]/2013 57 F 14 Tail DP >20 NA Por NEC NA None NDR (72)
Eguchi [16]/2013 73 F 12 Tail DP, S NA NA NA 1 None NA NDR (4)
Fenech [17]/2013 76 F 16 Tail DP, S NA <2 W 1 Surround None NA
Present case/2014 71 M 15 Head SSpPD >20 >20 Por NEC Surround, LN, duodenum None NDR (24)
Karavias [5]/2015 75 F 17 Body/tail DP, S, RMD NA 10 NA 2 Lt-kidney, Lt adrenal, PALN,
liver, omentum
None NDR (60)
Vasikasin [18]/2016 15 M 12.5 Tail DP, S 1–2 3–4 NA 1 None None NDR (6)
Martino [19]/2016 49 F 21 Head/body/tail Debulking >15 15 NA 2 Surround, LN, liver, axillary,
and mediastinal
Remnant AD (36)
Ki-67 Ki-67 index, Mitosis mitoses per 10 high-power fields, Meta Site metastatic sites, DP distal pancreatectomy, S splenectomy, NA not available, W well-differentiated neuroendocrine tumor, NDR no disease recurrence,
NEC neuroendocrine carcinoma, WDEC well-differentiated neuroendocrine carcinoma, Surround surrounding adipose tissue, LN lymph node, PD pancreaticoduodenectomy, E enuclation, NO no operation, DOD died of
other disease, PpPD pylorous-preserving PD, RLM resection of liver metastases, AD alive with disease, DMD died of metastatic disease, Por poorly differentiated neuroendocrine tumor, SSpPD subtotal stomach-preserving











there was a slight male preponderance (male/female
ratio, 1.14:1). Those patterns are similar to those of
non-giant insulinomas.
Tumor location within the pancreas was available for
42 patients. Tumors in a single segment of the pancreas
had a predilection for the tail (n = 22); involvement of
both the body and tail was seen in 12 patients. Giant tu-
mors occur more frequently in the body and tail of the
pancreas because they can grow freely there without
causing mass effects or mechanical obstruction [12]. Even
huge masses in the head of the pancreas rarely present
with gastric outlet obstruction or obstructive jaundice be-
cause insulinomas generally enlarge slowly and do not
massively invade adjacent vital organs.
Surgical resection had been performed in 36 (81.8%)
of all cases studied; the procedures comprising distal
pancreatectomy (combined with resection or ablation of
hepatic metastases) in 23 (4) cases, pancreaticoduode-
nectomy in 3, tumor resection in 5, and total pancrea-
tectomy in 1 case. No patient had undergone combined
resection and reconstruction of the portal vein or hepatic
artery. Complete resection should be performed; however,
removing 90% of the tumor is acceptable. Surgery is justi-
fied for functional advanced neuroendocrine tumors, the
aims being to control symptoms, improve quality of life,
and extend survival rate compared with conservative
treatment [19]. Seven of 19 patients with metastases or
recurrence had received sequential multimodal therapy
(systemic chemotherapy, chemoembolization, ablation,
and resection of liver metastases). These aggressive ther-
apies can prolong the survival of patients with malignant
insulinoma, even in the presence of liver metastases [20].
The diameter of these patient’s tumors ranged between
9 and 21 cm (median, 12 cm). Most insulinomas become
symptomatic when very small, allowing early detection
and prompt surgical treatment, possibly before they can
metastasize. The severity of hypoglycemia varies from pa-
tient to patient and has no direct relationship with tumor
burden [10]. Sugiyama et al. [7] suggested that giant insu-
linoma initially diagnosed as non-functioning pNETs may
secondarily become functioning.
Twenty-five (55.6%) of the cases of giant insulinoma
reviewed had metastases at presentation, this percentage
being higher than the 10% reported in most insulinoma
series [2]. At the first surgery, six patients had involve-
ment of the multiple organs, seven had liver metastases
only, and 12 had locally advanced disease such as invasion
of the surrounding adipose tissues or/and lymph node in-
volvement. Eight cases had developed recurrences, the
major site of metastases being the liver.
Follow-up data were available for 41 of the published
cases. Duration of follow-up of 24 cases who had no
recurrences ranged between 3 months and 23 years
(median 18 months). Seven cases of the 11 fatal cases
were reported before 1980. The overall survival of all
patients who died with disease ranged between 1 month
and 13 years (median, 2 years), whereas patients of
non-giant malignant insulinoma with distant metasta-
ses had a median survival of <2 years [11]. Six cases
alive with disease had been followed-up for 15 months
to 17 years (median, 4 years).
Since 2001, the mitotic activity, Ki-67 index, and grade
have been reported for 17 patients with giant insulinomas
(Table 2) [5–7, 12–14, 16–19, 21]. We compared the
grade, the rate of metastases and duration of follow-up of
18 cases, including the present case. The Ki-67 index
was <2% in eight cases; the only three cases with a Ki-
67 index of ≥20% were diagnosed as having NECs. Four,
three, and one patient had no metastases from G1/G2/
NEC at surgery, respectively, whereas four, four, and
one had synchronous metastases, respectively. Unex-
pectedly, there was no difference in proportion of G1/
G2/NEC in patients with versus without synchronous
metastases. The median durations of follow-up by
grade were as follows: 12 months (G1), 12 months
(G2), and 31 months (NEC); the duration of follow-up
for NECs being longer than expected. We anticipated
that patients with giant insulinoma and higher Ki-67 in-
dexes would have worse prognoses; however, we identi-
fied no relationship between grade and survival. In our
small case series, we were unable to identify any correl-
ation between grade and biological behavior of giant
insulinomas.
Conclusions
Giant insulinomas more frequently exhibit malignant be-
havior, such as local invasion, lymph node involvement,
and liver metastasis, than smaller ones. Metastatic dis-
ease is present at surgery in 56% of cases of giant insuli-
noma. Unexpectedly, there was no relationship between
grade of pNET and rate of metastases or survival in this
small case series. Identification of useful biological markers
is necessary, as is development of anti-tumor agents for
liver metastases.
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